[5']adenylic acid L-glutamine anhydride | 108884-05-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: [5']adenylic acid L-glutamine anhydride
• 英文别名: [5']Adenylsaeure-L-glutamin-anhydrid；[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] (2S)-2,5-diamino-5-oxopentanoate
• CAS: 108884-05-5
• 化学式: C₁₅H₂₂N₇O₉P
• 分子量: 475.355
• InChiKey: WHAIODPVLKHEHE-LTOLZBHSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.9
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  261
• 氢给体数：
  6
• 氢受体数：
  14

文献信息

• [EN] SULFANIDE ADENOSINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS D'ADÉNOSINE SULFANIDE ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2016201374A1

  公开（公告）日：2016-12-15

  Described herein are sulfamide adenosine derivatives of Formula (I) or (II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods, uses, and kits involving the inventive compounds or pharmaceutical compositions for treating and/or preventing proliferative diseases (e.g., cancers, inflammatory diseases, and autoimmune diseases) or infectious diseases (e.g., bacterial infections, viral infections, fungal infections, and parasitic diseases) in a subject. The compounds and pharmaceutical compositions as described herein are thought to inhibit aminoacyl tRNA synthetase activity in a biological sample or subject to achieving the treatment of proliferative diseases or infectious diseases.

  本文描述了化合物的磺胺基腺苷衍生物，其化学式为(I)或(II)，以及其药学上可接受的盐和药物组合物。还提供了涉及创新化合物或药物组合物用于治疗和/或预防增殖性疾病（例如癌症、炎症性疾病和自身免疫疾病）或传染性疾病（例如细菌感染、病毒感染、真菌感染和寄生虫病）的方法、用途和试剂盒。据认为，本文描述的化合物和药物组合物能够通过抑制生物样本或受试者中的氨酰tRNA合成酶活性来实现治疗增殖性疾病或传染性疾病。
• Methods for Altering Gene Expression and Methods of Treatment Utilizing Same
  申请人：Detloff Peter J.

  公开号：US20080318884A1

  公开（公告）日：2008-12-25

  The present disclosure describes methods for altering the expression of a target gene comprising a rare cluster of codons, including, but not limited to, trinucleotide repeats. The method utilizes, in part, on amino acid deprivation or the limiting of specific charged tRNAs. The methods for altering target gene expression may be used in treatment methods to treat diseases in a subject organism in need of such treatment. Such methods for altering target gene expression have not been heretofore recognized in the art. Exemplary diseases that may be treated using the methods of the present disclosure include any disease where altering the expression of the target gene would provide treatment. Such diseases include all forms of cancer, ageing, infectious disease, metabolic disorders, inflammation, neurological disorders, diabetes, psychiatric disorders and diseases associated with trinucleotide repeats.
• [EN] METHODS OF ALTERING GENE EXPRESSION AND METHODS OF TREATMENT UTILIZING SAME<br/>[FR] PROCEDES DE MODIFICATION D'EXPRESSION GENIQUE ET METHODES DE TRAITEMENT METTANT EN OEUVRE LESDITS PROCEDES
  申请人：UAB RESEARCH FOUNDATION

  公开号：WO2006105038A2

  公开（公告）日：2006-10-05

  [EN] The present disclosure describes methods for altering the expression of a target gene comprising a rare cluster of codons, including, but not limited to, trinucleotide repeats. The method utilizes, in part, on amino acid deprivation or the limiting of specific charged tRNAs. The methods for altering target gene expression may be used in treatment methods to treat diseases in a subject organism in need of such treatment. Such methods for altering target gene expression have not been heretofore recognized in the art. Exemplary diseases that may be treated using the methods of the present disclosure include any disease where altering the expression of the target gene would provide treatment. Such diseases include all forms of cancer, ageing, infectious disease, metabolic disorders, inflammation, neurological disorders, diabetes, psychiatric disorders and diseases associated with trinucleotide repeats.
  [FR] L'invention concerne des procédés permettant de modifier l'expression d'un gène cible comprenant un cluster rare de codons, entre autres, des répétitions trinucléotidiques. Ce procédé utilise, en partie, la privation d'acides aminés ou la limitation d'ARN de transfert chargés spécifiques. Ces procédés de modification de l'expression d'un gène cible peuvent être mis en oeuvre dans des méthodes de traitement visant à traiter des maladies dans l'organisme de patients nécessitant un tel traitement. Des exemples de maladies pouvant être traitées par la mise en oeuvre des procédés selon l'invention comprennent toutes les maladies susceptibles d'être traitées par la modification de l'expression d'un gène cible. Ces maladies comprennent toutes les formes de cancer, le vieillissement, les maladies infectieuses, les troubles métaboliques, les inflammations, les troubles neurologiques, le diabète, les troubles psychiatriques et les maladies associées à des répétitions trinucléotidiques.